GSK Presents Results of 5-in-1 Meningococcal ABCWY Vaccine Candidate at ESPID 2023
Shots:
- The preliminary results from the P-III trial evaluating MenABCWY, administered as two doses given 6mos. apart in 3650 patients aged 10-25yrs. in the US, Canada, Czech Republic, Estonia, Finland, Turkey & Australia
- The trial met all 1EPs & showed a non-inferiority compared to 2 doses of Bexsero (meningococcal group B vaccine) & 1 dose of Menveo (meningococcal group A, C, W-135 & Y conjugate vaccine), was well tolerated with a safety profile consistent with Bexsero & Menveo
- In a separate confirmatory arm, the vaccine showed immunological effectiveness against 110 diverse MenB invasive strains. The company works closely with regulatory agencies to review the P-III data & the results will be submitted to a peer-reviewed scientific journal
Ref: GSK | Image: GSK
Related News:- GSK’s Arexvy Receives the US FDA’s Approval for the Prevention of Lower Respiratory Tract Disease in Individuals Aged ≥60 Years
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
